[PDF][PDF] Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
NK Cheung, H Lazarus, FD Miraldi… - Journal of clinical …, 1987 - researchgate.net
NK Cheung, H Lazarus, FD Miraldi, CR Abramowsky, S Kallick, UM Saarinen, T Spitzer…
Journal of clinical oncology, 1987•researchgate.netThe murine IgG3 monoclonal antibody (MoAb) 3F8, specific for the ganglioside GD2,
activates human complement, is active in antibody-dependent cellmediated cytotoxicity
(ADCC), and can target specifically to human neuroblastoma in patients with metastatic
disease. In a phase I study, 3F8 was administered intravenously (IV) to 17 patients with
metastatic GD2 positive neuroblastoma or malignant melanoma at doses of 5, 20, 50, and
100 mg/m2. Serum 3F8 levels achieved were proportional to the dose of 3F8 infused …
activates human complement, is active in antibody-dependent cellmediated cytotoxicity
(ADCC), and can target specifically to human neuroblastoma in patients with metastatic
disease. In a phase I study, 3F8 was administered intravenously (IV) to 17 patients with
metastatic GD2 positive neuroblastoma or malignant melanoma at doses of 5, 20, 50, and
100 mg/m2. Serum 3F8 levels achieved were proportional to the dose of 3F8 infused …
The murine IgG3 monoclonal antibody (MoAb) 3F8, specific for the ganglioside GD2, activates human complement, is active in antibody-dependent cellmediated cytotoxicity (ADCC), and can target specifically to human neuroblastoma in patients with metastatic disease. In a phase I study, 3F8 was administered intravenously (IV) to 17 patients with metastatic GD2 positive neuroblastoma or malignant melanoma at doses of 5, 20, 50, and 100 mg/m2. Serum 3F8 levels achieved were proportional to the dose of 3F8 infused. However, serum antimouse antibody levels did not increase with the amount of 3F8 administered. Toxicities included pain, hypertension,
researchgate.net